{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:13:23Z","timestamp":1788599603763,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Lipids and lipoproteins have established roles in calcific atherosclerosis, but there is less awareness of their role in calcific aortic valve disease (CAVD). Clinical studies link CAVD with severe hypercholesterolemia, and genetic studies consistently link it with lipoprotein little (a) [Lp(a)], a major carrier of oxidized phospholipids. Given the remarkable similarities between calcific atherosclerotic plaques and calcific aortic valves, lipids are incriminated. Hence, lipid-lowering therapies used for atherosclerosis have been tested in CAVD, but results have been inexplicably disappointing. New evidence for the importance of lipids, despite failure of lipid-lowering, and new concepts in diagnostic and therapeutic approaches are discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Evidence supports a key role of Lp(a) levels in CAVD. Potential diagnostic advances include pH-sensitive-fluorescence probes for visualizing lipid droplets in valves and identification of natural antibodies to modified LDL that associate inversely with CAVD. Potential therapeutic advances include Lp(a) lowering, SGLT2 inhibition, and reactivation of soluble guanylate cyclase. Trial outcomes currently remain mixed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Recent studies clarify the mechanisms by which lipids, lipoproteins, and Lp(a) contribute to CAVD. New potential diagnostic techniques include screening for natural antibodies and visualizing lipid deposits. New therapeutic agents include oligonucleotides and nanoparticles. New clinical trials are underway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mol.0000000000001053","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:58:44Z","timestamp":1786625924000},"page":"185-190","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Lipids and lipoproteins in calcific aortic valve disease"],"prefix":"10.1097","volume":"37","author":[{"given":"Olcay","family":"Aksoy","sequence":"first","affiliation":[{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Tintut","sequence":"additional","affiliation":[{"name":"Department of Medicine"},{"name":"Department of Physiology"},{"name":"Department of Orthopaedic Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Demer","sequence":"additional","affiliation":[{"name":"Department of Medicine"},{"name":"Department of Physiology"},{"name":"Department of Bioengineering, University of California, Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"R1-20260905","doi-asserted-by":"crossref","first-page":"126069","DOI":"10.1016\/j.talanta.2024.126069","article-title":"A lipid activated color switchable probe for the imaging of diseased aortic valves","volume":"275","author":"Zhuang","year":"2024","journal-title":"Talanta"},{"key":"R2-20260905","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00604-025-07613-z","article-title":"Imaging lipid deposition induced by local hypoxia in degenerative aortic valve disease using a twisted intramolecular charge transfer (TICT)-based lipid droplet-targeting probe","volume":"192","author":"Chai","year":"2025","journal-title":"Mikrochim Acta"},{"key":"R3-20260905","doi-asserted-by":"crossref","first-page":"8273","DOI":"10.1038\/s41467-024-52621-x","article-title":"Lipid droplets sequester palmitic acid to disrupt endothelial ciliation and exacerbate atherosclerosis in male mice","volume":"15","author":"Tan","year":"2024","journal-title":"Nat Commun"},{"key":"R4-20260905","doi-asserted-by":"crossref","first-page":"102505","DOI":"10.1016\/j.jacadv.2025.102505","article-title":"Aortic stenosis in homozygous familial hypercholesterolemia: the Canadian HoFH Registry","volume":"5","author":"Erzingatzian","year":"2026","journal-title":"JACC Adv"},{"key":"R5-20260905","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R6-20260905","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-20260905","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-20260905","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"R9-20260905","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jacbts.2017.03.015","article-title":"Lipoprotein(a) induces human aortic valve interstitial cell calcification","volume":"2","author":"Yu","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"R10-20260905","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s40001-025-03071-8","article-title":"Association of lipoprotein(a) and LPA gene with calcific aortic valve disease","volume":"30","author":"Yu","year":"2025","journal-title":"Eur J Med Res"},{"key":"R11-20260905","doi-asserted-by":"crossref","first-page":"119174","DOI":"10.1016\/j.atherosclerosis.2025.119174","article-title":"Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening","volume":"403","author":"Khan","year":"2025","journal-title":"Atherosclerosis"},{"key":"R12-20260905","doi-asserted-by":"crossref","first-page":"oeaf068","DOI":"10.1093\/ehjopen\/oeaf068","article-title":"Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase\/fructose-2,6-biphosphatase 3-mediated glycolysis in Lp(a)-induced valve inflammation","volume":"5","author":"Peletier","year":"2025","journal-title":"Eur Heart J Open"},{"key":"R13-20260905","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12872-025-04892-5","article-title":"Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells","volume":"25","author":"Zulkapli","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"R14-20260905","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/cvr\/cvaf142","article-title":"Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study","volume":"121","author":"Moroney","year":"2025","journal-title":"Cardiovasc Res"},{"key":"R15-20260905","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/cvr\/cvaf159","article-title":"Oxidized LDL-induced FOXS1 mediates cholesterol transport dysfunction and inflammasome activation to drive aortic valve calcification","volume":"121","author":"Jiang","year":"2025","journal-title":"Cardiovasc Res"},{"key":"R16-20260905","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","article-title":"Oxidized phospholipids and calcific aortic valvular disease","volume":"84","author":"Bhatia","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R17-20260905","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12872-025-05037-4","article-title":"Aortic valve stenosis and osteoporosis: insights from a mouse model","volume":"25","author":"Billig","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"R18-20260905","doi-asserted-by":"crossref","first-page":"114036","DOI":"10.1016\/j.isci.2025.114036","article-title":"Targeted proteomics reveals immune protein patterns in serum from patients with calcific aortic stenosis","volume":"28","author":"Mallia","year":"2025","journal-title":"iScience"},{"key":"R19-20260905","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biomechanics5040099","article-title":"Influence of coronary flow and left ventricular outflow tract velocity on LDL accumulation and calcification in aortic valve leaflets","volume":"5","author":"Raza-Taimuri","year":"2025","journal-title":"Biomechanics (Basel)"},{"key":"R20-20260905","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12944-026-02884-8","article-title":"Decoding calcific aortic valve disease: superior predictive power of time-weighted lipoprotein(a)","volume":"25","author":"Jiang","year":"2026","journal-title":"Lipids Health Dis"},{"key":"R21-20260905","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1039\/D5TB00531K","article-title":"A pH-responsive fluorescence nanosystem for imaging lipid deposition in diseased aortic valves","volume":"13","author":"Li","year":"2025","journal-title":"J Mater Chem B"},{"key":"R22-20260905","doi-asserted-by":"crossref","first-page":"e041524","DOI":"10.1161\/JAHA.125.041524","article-title":"Anti-malondialdehyde low-density lipoprotein antibodies and valvular calcification: a substudy of the SCOT-HEART Trial","volume":"14","author":"Hartley","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R23-20260905","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Aim-High-Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-20260905","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.3390\/ijms262311259","article-title":"Early supplementation with branched-chain amino acids ameliorates lipid retention in aortic valves of apoe-knockout mice","volume":"26","author":"Shishkova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R25-20260905","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12967-026-07686-1","article-title":"Precision RNA interference of Smad3 and Runx2 via dual targeting nanocarriers mitigates aortic valve disease","volume":"24","author":"Voicu","year":"2026","journal-title":"J Transl Med"},{"key":"R26-20260905","first-page":"1690","article-title":"Angiotensin II receptor blockers are associated with reduced valvular fibrosis in women with aortic stenosis","volume":"40","author":"Carter-Storch","year":"2024","journal-title":"Can J Cardiol"},{"key":"R27-20260905","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ehjci\/jev043","article-title":"A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial)","volume":"16","author":"Bull","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"R28-20260905","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.121.053708","article-title":"Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial","volume":"143","author":"Pawade","year":"2021","journal-title":"Circulation"},{"key":"R29-20260905","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41401-023-01217-0","article-title":"Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"R30-20260905","doi-asserted-by":"crossref","first-page":"107376","DOI":"10.1016\/j.vph.2024.107376","article-title":"Effects of Empagliflozin on vascular and skeletal mineralization in hyperlipidemic mice","volume":"155","author":"Kalanski","year":"2024","journal-title":"Vascul Pharmacol"},{"key":"R31-20260905","article-title":"SGLT2 inhibitors in heart failure with reduced ejection fraction: a retrospective cohort analysis of sex-specific cardiovascular outcomes","volume":"202","author":"Ibrahim","year":"2026","journal-title":"Curr Cardiol Rev"},{"key":"R32-20260905","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/CIRCULATIONAHA.123.066523","article-title":"Reactivation of oxidized soluble guanylate cyclase as a novel treatment strategy to slow progression of calcific aortic valve stenosis: preclinical and randomized clinical trials to assess safety and efficacy","volume":"151","author":"Zhang","year":"2025","journal-title":"Circulation"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOL.0000000000001053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:00:28Z","timestamp":1788598828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MOL.0000000000001053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000001053","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}